Connect With Us
Subscribe Now
Log In
Home
News
Education
Health
Tech
STEM
Advanced Manufacturing & Logistics
Life Sciences
Ag INnovation
INPower
Videos
Big Wigs
Submit Big Wigs
Events
Innovate Southwest Indiana â Evansville
Innovate West Central Indiana – Terre Haute
Innovate East Central – Muncie
Innovate Northeast Indiana – Fort Wayne
Newsletters
Podcasts
On-Air
TV & Radio Listings
Content Studio
Sponsored Content
Contact
About IIB
Meet the Team
Contact Us
Advertise
Gift Cards
Flagship Stations
Gerry’s Message
Speaking Engagement Request
Search
GO
Connect With Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Scholar Rock Holding Corporation - Common Stock
(NQ:
SRRK
)
46.75
-1.25 (-2.60%)
Streaming Delayed Price
Updated: 12:49 PM EST, Feb 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Scholar Rock Holding Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
↗
February 22, 2026
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Via
The Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
↗
February 22, 2026
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Via
The Motley Fool
Topics
Regulatory Compliance
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
↗
February 22, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
↗
February 22, 2026
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
↗
February 22, 2026
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock to Present at Upcoming Investor Conferences
February 18, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
February 10, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
↗
February 01, 2026
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From
Scholar Rock
Via
Business Wire
Scholar Rock Highlights 2026 Strategic Priorities
January 12, 2026
From
Scholar Rock, Inc.
Via
Business Wire
Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Scholar Rock, Inc.
Via
Business Wire
Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety
December 24, 2025
As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2025
From
Scholar Rock
Via
Business Wire
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
↗
December 03, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via
The Motley Fool
Topics
Regulatory Compliance
Scholar Rock to Present at Upcoming Investor Conferences
November 18, 2025
From
Scholar Rock
Via
Business Wire
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session.
↗
November 14, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Why Is Scholar Rock Holding Stock Climbing Today?
↗
November 14, 2025
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab.
Via
Benzinga
Why Did Scholar Rock Soar 26% Today?
↗
November 14, 2025
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.
Via
Stocktwits
Topics
Earnings
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher
↗
November 14, 2025
Via
Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Via
Chartmill
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
↗
November 14, 2025
Via
Benzinga
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations
↗
November 14, 2025
Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss.
Via
Chartmill
Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 14, 2025
From
Scholar Rock
Via
Business Wire
Earnings Scheduled For November 14, 2025
↗
November 14, 2025
Via
Benzinga
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
↗
November 13, 2025
Lucid, Avis, Hims & Hers Health and Upstart are some of the most heavily shorted stocks right now. Here's a look at the top ten.
Via
Benzinga
What to Expect from Scholar Rock Holding's Earnings
↗
November 13, 2025
Via
Benzinga
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 12, 2025
From
Scholar Rock
Via
Business Wire
3 Beaten-Down Stocks With Rebound Potential This Earnings Season
↗
November 12, 2025
Via
MarketBeat
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
November 04, 2025
From
Scholar Rock
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.